Project Grant R01AI182513
Award Date
5/1/25
Completion Date
4/30/29
Dollars Obligated
$587K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
This Project Grant award of $1,373,790 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to optimize the structural features of the antimalarial drug candidate ELQ-596 to develop a next generation of ELQ compounds for once-monthly oral malaria prophylaxis in humans. The primary awardee, Oregon Health & Science University, will lead this research effort in collaboration with Drexel University and the Portland VA...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $206,116 to Oregon Health & Science University (OHSU) to develop new 4-aminoquinoline compounds as potential therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest malaria parasite. The key objectives are to: 1) use an iterative medicinal chemistry approach to optimize the lead...
This Project Grant award, totaling $648,448.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research to define the complex genetic basis of Plasmodium falciparum resistance to artemisinin and quinine, as well as identify resistance-refractory therapeutics. Specifically, the research aims to: Investigate the role of candidate genes MRP1 and ARPS10 in mitigating...
This $949,200 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to investigate the mechanisms underlying severe malarial anemia. The study aims to determine whether elevated levels of the enzyme xanthine oxidase (XO) contribute to the loss of uninfected red blood cells, a major factor in malaria-induced anemia. The research will examine the effects of XO from patient plasma on the...
This $777,072 five-year Project Grant award under the National Institute of Allergy and Infectious Diseases' (NIAID) Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to develop an understanding of factors that drive the efficacy and resistance acquisition risk for a new class of fast-acting antimalarial drugs called ATP4 inhibitors (ATP4I), including SJ733 which recently completed Phase 2A trials. The research will examine the efficacy and resistance patterns...
This $467,400 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a platform for quantifying levels of antimalarial drugs, including lumefantrine, amodiaquine, and piperaquine, in dried blood spot (DBS) samples. The research team at the University of California, San Francisco (UCSF) will employ volumetric absorptive microsampling (VAMS) techniques to collect precise DBS...
This $400,347 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to profile malarial lipid biosynthesis and key acyl-coenzyme A synthetase activities in the malaria parasite Plasmodium falciparum. The two-year project, running from July 2024 to May 2026, will develop a new "fatty acid alkyne profiling" approach to systematically analyze fatty acid uptake...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a five-year, $738,445 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Drexel University to develop a multivalent mRNA-based malaria vaccine. The key objectives are to: Optimize an mRNA vaccine targeting the P. falciparum circumsporozoite protein (PfCSP) to drive durable antibody and cell-mediated immune responses against pre-erythrocytic stage parasites. Design, produce, and evaluate an mRNA...
This $1,845,103 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to define the immunogenic landscape of early mosquito-stage Plasmodium falciparum parasites. The goal is to accelerate the discovery of malaria transmission-blocking vaccines. The research involves using mass spectrometry-based proteomics to comprehensively catalog surface-exposed proteins in P. falciparum...
The Department of Health and Human Services, National Institute of Allergy and Infectious Diseases (NIAID) awarded a $459,131 Project Grant to The Ohio State University to conduct research on the essential functions of the mitochondrion in malaria parasites. The project aims to expand the druggable parasite proteome across all stages of malaria infection, with a focus on the parasite mitochondrion as a promising source of new drug targets. Through improved genetic methods, the researchers will...